Figure 5. Co‐targeting of cMet and Plk1 induces apoptosis and reduces tumor size in non–small‐cell lung cancer.

• A–D
  Mice bearing epithelial (red text) and mesenchymal (blue text) non–small‐cell lung cancer tumors were treated with vehicle control, volasertib (30 mg/kg per week intravenously), tepotinib (25 mg/kg per day orally), or the combination for 5 weeks to generate tumor growth curves of patient‐derived xenografts (PDX; A) and cell line xenografts (C). The percent change in tumor volume at the end of treatment (normalized to day zero) was calculated with each data point representing an individual mouse, and the bar is the mean value ± standard error of 10 mice for each group (B, D).
• E
  Tumor growth curve of mesenchymal PDX TC424 (top) and cell line xenograft Calu6 (bottom) upon treatment for 5 weeks and after cessation of treatment (recovery phase). Data are means ± standard error of the mean from five mice for each group.
• F
  Kaplan–Meier survival curves for mesenchymal PDX TC424 (top) and cell line xenograft Calu6 (bottom) with death due to excessive tumor burden as the endpoint.
• G
  Quantification of TUNEL‐positive cells in paraffin‐embedded xenograft tissue sections. Data are means ± standard error of the mean from six mice for each group.

Data information: Significant differences using two‐way analysis of variance with Bonferroni or Benjamini–Hochberg correction for multiple comparisons are indicated. *P < 0.01.Source data are available online for this figure.